Value of KL-6 in Rheumatoid Arthritis-Associated ILD

Study Overview
=================
Brief Summary
-----------------
Evaluation of serum KL6 level in rheumatoid arthritis-associated interstitial lung disease (RA-ILD).

Detailed Description
-----------------
Rheumatoid arthritis (RA) is one of the most common connective tissue diseases (CTD). Its prevalence is increasing worldwide . It is responsible for a considerable number of hospital visits in Egyptian Hospitals . Pumlonary involvement is common in rheumatoid arthritis (RA). Interstitial lung disease associated rheumatoid arthritis (ILD-RA) is responsible for significant morbidity and mortality . Krebs von den Lungen 6 (KL-6) is a mucin like glycoprotein that is found mainly on the surface of type II pneumocytes as well as in bronchiolar epithelial cells . It has chemotactic and anti-apoptotic action on fibroblasts , hence, it is considered as a marker of pulmonary epithelial cell injury . Krebs von den Lungen-6 (KL6) has been found to be a valuable diagnostic tool in many interstitial lung diseases. KL6 was found to be a valuable prognostic marker, as well as a marker for disease severity in idiopathic pulmonary fibrosis (IPF) . KL6 was found useful as well in predicting in-hospital mortality in patients with Acute exacerbation of interstitial lung disease (AE-ILD) . KL-6 serum level can serve as a diagnostic marker for connective tissue disease-associated interstitial lung disease (CTD-ILD). It can be used to monitor effectiveness of medical treatment and patient response to pulse therapy . Its value in Rheumatoid Arthritis-associated Interstitial Lung Disease (RA-ILD) has not yet been adequately investigated.

Official Title
-----------------
Value of Krebs Von Den Lungen-6 Assay in Rheumatoid Artheritis-associated Interstitial Lung Disease

Conditions
-----------------
Rheumatoid Arthritis-Associated Interstitial Lung Disease

Intervention / Treatment
-----------------
* Diagnostic Test: Krebs von den Lungen-6 (KL6)


Participation Criteria
=================
Eligibility Criteria
-----------------
Diagnosis of RA will be based on American College of Rheumatology/European League against Rheumatism (ACR-EULAR) classification criteria 2010. Inclusion Criteria: all patients have rheumatoid arthritis-associated interstitial lung disease Exclusion Criteria: Patients with any evidence of infection will be excluded.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Rheumatoid Arthritis-associated Interstitial Lung Disease<br>Krebs von den Lungen-6 (KL6) | Diagnostic Test: Krebs von den Lungen-6 (KL6)<br>* KL-6 concentration will be measured using Sandwich ELISA technique (SinoGene Clone Biotech, China).<br>* Other names: HRCT Chest;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| KL-6 | detect its serum level | one day | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Spirometry | FEV1, FVC, FVC/FEV1 will be measured. | one day | 
| HRCT chest | It will be will be assessed by the radiologist to determine pulmonary involvement. | one day |